UA81365C2 - Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition - Google Patents

Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition Download PDF

Info

Publication number: UA81365C2
Authority: UA; Ukraine
Prior art keywords: solution; added; naphthyridine; trifluoromethyl; pyran
Prior art date: 2003-10-27

Application number

UAA200605772A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-27

Filing date

2004-10-25

Publication date

2007-12-25

2004-10-25 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2007-12-25 Publication of UA81365C2 publication Critical patent/UA81365C2/uk

Links

238000000034 method Methods 0.000 title claims description 16
102000009410 Chemokine receptor Human genes 0.000 title claims description 3
108050000299 Chemokine receptor Proteins 0.000 title claims description 3
230000000694 effects Effects 0.000 title claims 2
239000008194 pharmaceutical composition Substances 0.000 title claims 2
150000003839 salts Chemical class 0.000 title description 9
239000002604 chemokine receptor CCR2 antagonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
201000010099 disease Diseases 0.000 claims abstract description 7
208000035475 disorder Diseases 0.000 claims abstract 4
230000004957 immunoregulator effect Effects 0.000 claims abstract 4
230000002757 inflammatory effect Effects 0.000 claims abstract 4
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 4
241000124008 Mammalia Species 0.000 claims description 2
238000012876 topography Methods 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 53
239000000243 solution Substances 0.000 description 52
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
239000000725 suspension Substances 0.000 description 32
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
239000000203 mixture Substances 0.000 description 26
239000007787 solid Substances 0.000 description 24
-1 amine salt Chemical class 0.000 description 19
230000015572 biosynthetic process Effects 0.000 description 19
239000011541 reaction mixture Substances 0.000 description 19
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
238000003786 synthesis reaction Methods 0.000 description 16
238000007792 addition Methods 0.000 description 15
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 14
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 14
238000005406 washing Methods 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
239000012458 free base Substances 0.000 description 11
239000010410 layer Substances 0.000 description 11
239000012044 organic layer Substances 0.000 description 11
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
230000003993 interaction Effects 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
239000007788 liquid Substances 0.000 description 8
238000004458 analytical method Methods 0.000 description 7
229940125904 compound 1 Drugs 0.000 description 7
238000001816 cooling Methods 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 6
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
229940077388 benzenesulfonate Drugs 0.000 description 5
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 5
238000001914 filtration Methods 0.000 description 5
238000005984 hydrogenation reaction Methods 0.000 description 5
239000013049 sediment Substances 0.000 description 5
KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 4
208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 description 4
LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
238000004821 distillation Methods 0.000 description 4
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
230000008569 process Effects 0.000 description 4
239000011734 sodium Substances 0.000 description 4
RWNXXQFJBALKAX-UHFFFAOYSA-N 1-(dipropoxymethoxy)propane Chemical compound CCCOC(OCCC)OCCC RWNXXQFJBALKAX-UHFFFAOYSA-N 0.000 description 3
YVKYZZSGAOUFGK-UHFFFAOYSA-N 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine Chemical compound C1CNCC2=CC(C(F)(F)F)=CN=C21 YVKYZZSGAOUFGK-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
239000012359 Methanesulfonyl chloride Substances 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940011051 isopropyl acetate Drugs 0.000 description 3
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 3
229950001870 spizofurone Drugs 0.000 description 3
239000001384 succinic acid Substances 0.000 description 3
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
VLMTYRPQKRSGJX-UHFFFAOYSA-N 3,4-dihydroxyoxane-4-sulfonic acid Chemical compound OC1COCCC1(O)S(O)(=O)=O VLMTYRPQKRSGJX-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
125000002820 allylidene group Chemical group [H]C(=[*])C([H])=C([H])[H] 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
OQGVPWWLCUMRCI-UHFFFAOYSA-N cyclopenten-1-amine Chemical compound NC1=CCCC1 OQGVPWWLCUMRCI-UHFFFAOYSA-N 0.000 description 2
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
NJZJVNYPVUWFRX-UHFFFAOYSA-N ethene;4-propoxyoxane Chemical compound C=C.CCCOC1CCOCC1 NJZJVNYPVUWFRX-UHFFFAOYSA-N 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000005457 ice water Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
239000002243 precursor Substances 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005341 toughened glass Substances 0.000 description 2
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical class C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
WBUHGSNIYBJEDA-UHFFFAOYSA-N 1-cyclopentyl-2-(oxan-2-yl)-3,4-dihydro-2h-1,5-naphthyridine Chemical compound C1CCCC1N1C2=CC=CN=C2CCC1C1OCCCC1 WBUHGSNIYBJEDA-UHFFFAOYSA-N 0.000 description 1
ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
ZOMRQKDCQLXWLC-UHFFFAOYSA-N 3-methoxypyran-2-one Chemical compound COC1=CC=COC1=O ZOMRQKDCQLXWLC-UHFFFAOYSA-N 0.000 description 1
SFWWGMKXCYLZEG-UHFFFAOYSA-N 3-methylmorpholine Chemical compound CC1COCCN1 SFWWGMKXCYLZEG-UHFFFAOYSA-N 0.000 description 1
BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
BXGOXDLHSNHTCX-UHFFFAOYSA-N 4,4-dimethoxyoxan-3-ol Chemical compound COC1(OC)CCOCC1O BXGOXDLHSNHTCX-UHFFFAOYSA-N 0.000 description 1
FNWWXCLMWLVPJX-UHFFFAOYSA-N 4-hydroxy-3-methylmorpholine Chemical compound CC1COCCN1O FNWWXCLMWLVPJX-UHFFFAOYSA-N 0.000 description 1
101000603223 Homo sapiens Nischarin Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
241000531897 Loma Species 0.000 description 1
241000680386 Meonis Species 0.000 description 1
ULMHMJAEGZPQRY-UHFFFAOYSA-N N-(tert-butoxycarbonyl)piperidin-2-one Chemical compound CC(C)(C)OC(=O)N1CCCCC1=O ULMHMJAEGZPQRY-UHFFFAOYSA-N 0.000 description 1
ITRICWPKNGCFHX-UHFFFAOYSA-N N-methoxyoxan-4-amine Chemical compound CONC1CCOCC1 ITRICWPKNGCFHX-UHFFFAOYSA-N 0.000 description 1
102100038995 Nischarin Human genes 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
244000263375 Vanilla tahitensis Species 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
QXHXMALPRIXDEU-UHFFFAOYSA-P [3-(dimethylamino)-2-[(dimethylazaniumyl)methyl]prop-2-enyl]-dimethylazanium Chemical compound CN(C)C=C(C[NH+](C)C)C[NH+](C)C QXHXMALPRIXDEU-UHFFFAOYSA-P 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000006256 asymmetric dihydroxylation reaction Methods 0.000 description 1
SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
ZJRWDIJRKKXMNW-UHFFFAOYSA-N carbonic acid;cobalt Chemical compound [Co].OC(O)=O ZJRWDIJRKKXMNW-UHFFFAOYSA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229910000001 cobalt(II) carbonate Inorganic materials 0.000 description 1
239000012045 crude solution Substances 0.000 description 1
VSYCRDXNSAXDIU-UHFFFAOYSA-N cyclopent-2-en-1-amine Chemical compound NC1CCC=C1 VSYCRDXNSAXDIU-UHFFFAOYSA-N 0.000 description 1
150000001940 cyclopentanes Chemical class 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
JMVOCSLPMGHXPG-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium Chemical compound [K+].[K+].[O-][Os]([O-])(=O)=O JMVOCSLPMGHXPG-UHFFFAOYSA-N 0.000 description 1
DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
235000005583 doda Nutrition 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000013504 emergency use authorization Methods 0.000 description 1
150000002084 enol ethers Chemical class 0.000 description 1
UMYZHWLYICNGRQ-UHFFFAOYSA-N ethanol;heptane Chemical compound CCO.CCCCCCC UMYZHWLYICNGRQ-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002129 infrared reflectance spectroscopy Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
239000010413 mother solution Substances 0.000 description 1
PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
WFRLANWAASSSFV-FPLPWBNLSA-N palmitoleoyl ethanolamide Chemical compound CCCCCC\C=C/CCCCCCCC(=O)NCCO WFRLANWAASSSFV-FPLPWBNLSA-N 0.000 description 1
XMGMFRIEKMMMSU-UHFFFAOYSA-N phenylmethylbenzene Chemical group C=1C=CC=CC=1[C]C1=CC=CC=C1 XMGMFRIEKMMMSU-UHFFFAOYSA-N 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
241000894007 species Species 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
PTSJTHMUTXBBGJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1CNCCC1=O PTSJTHMUTXBBGJ-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
238000012546 transfer Methods 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)

UAA200605772A 2003-10-27 2004-10-25 Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition UA81365C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51473503P	2003-10-27	2003-10-27
PCT/US2004/035069 WO2005044264A1 (en)	2003-10-27	2004-10-25	Ccr-2 antagonist salt

Publications (1)

Publication Number	Publication Date
UA81365C2 true UA81365C2 (en)	2007-12-25

Family

ID=34572774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200605772A UA81365C2 (en)	2003-10-27	2004-10-25	Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition

Country Status (21)

Country	Link
US (1)	US7473696B2 (de)
EP (1)	EP1682135B1 (de)
JP (1)	JP4542550B2 (de)
KR (1)	KR20060101476A (de)
CN (1)	CN1870998B (de)
AT (1)	ATE517622T1 (de)
AU (1)	AU2004287416C1 (de)
BR (1)	BRPI0415836A (de)
CA (1)	CA2543201C (de)
CO (1)	CO5690606A2 (de)
EC (1)	ECSP066524A (de)
IL (1)	IL175009A0 (de)
IS (1)	IS8400A (de)
MA (1)	MA28104A1 (de)
MX (1)	MXPA06004647A (de)
NO (1)	NO20062377L (de)
NZ (1)	NZ546447A (de)
RU (1)	RU2317295C1 (de)
UA (1)	UA81365C2 (de)
WO (1)	WO2005044264A1 (de)
ZA (1)	ZA200602752B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY129850A (en)	2002-04-29	2007-05-31	Merck Sharp & Dohme	Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060030582A1 (en) *	2002-04-29	2006-02-09	Demartino Julie	Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
GEP20115290B (en)	2002-11-27	2011-09-26	Incyte Corp	3-aminopyrrolidine derivatives as modulators of chemokine receptors
US7393844B2 (en) *	2003-03-18	2008-07-01	Merck & Co., Inc.	Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
AR045875A1 (es) *	2003-10-27	2005-11-16	Merck & Co Inc	Procedimiento para la preparacion del antagonista ccr-2
UA82917C2 (en)	2003-12-18	2008-05-26		3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptor
KR100837019B1 (ko)	2004-05-11	2008-06-10	인사이트 코포레이션	케모카인 수용체 조절제로서3-(4-헤테로아릴사이클로헥실아미노)사이클로펜탄카복스아마이드
GB0413605D0 (en) *	2004-06-17	2004-07-21	Addex Pharmaceuticals Sa	Novel compounds
KR100856156B1 (ko)	2004-06-28	2008-09-03	인사이트 코포레이션	케모카인 수용체의 조절자로서의3-아미노사이클로펜탄카복스아마이드
AU2005259983B2 (en)	2004-06-28	2011-07-28	Incyte Corporation	3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CA2669917A1 (en)	2006-11-17	2008-05-22	Dawn M. George	Aminopyrrolidines as chemokine receptor antagonists
US20090076065A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched mk-0812
US7741327B2 (en)	2008-04-16	2010-06-22	Hoffmann-La Roche Inc.	Pyrrolidinone glucokinase activators
US8178689B2 (en)	2010-06-17	2012-05-15	Hoffman-La Roche Inc.	Tricyclic compounds
WO2012125663A2 (en) *	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
WO2013149376A1 (en)	2012-04-02	2013-10-10	Abbott Laboratories	Chemokine receptor antagonists
EP2962691A4 (de)	2013-02-28	2016-08-31	Santen Pharmaceutical Co Ltd	Mittel zur prävention oder behandlung von erkrankungen der hinteren teile des auges mit einem tetrahydropyranyl-amino-cyclopentylcarbonyl-tetrahydropyridopyridin-derivat als wirkstoff
RU2726206C2 (ru)	2015-05-21	2020-07-09	Кемосентрикс, Инк.	Модуляторы ccr2
WO2019060820A1 (en)	2017-09-25	2019-03-28	Chemocentryx, Inc.	POLYTHERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR
WO2019136368A2 (en)	2018-01-08	2019-07-11	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
US20190269664A1 (en)	2018-01-08	2019-09-05	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
CN112341350A (zh) *	2020-10-19	2021-02-09	江苏威奇达药业有限公司	酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RO108347B1 (ro) *	1989-10-30	1994-04-28	Bellon Labor Sa Roger	DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
GB9417249D0 (en) *	1994-08-26	1994-10-19	Wellcome Found	A novel salt
JPH09291034A (ja) *	1996-02-27	1997-11-11	Yoshitomi Pharmaceut Ind Ltd	縮合ピリジン化合物およびその医薬としての用途
RU2174123C2 (ru) *	1996-10-28	2001-09-27	Новартис Аг	Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
US6312689B1 (en) *	1998-07-23	2001-11-06	Millennium Pharmaceuticals, Inc.	Anti-CCR2 antibodies and methods of use therefor
FR2787790A1 (fr) *	1998-12-23	2000-06-30	Sanofi Sa	Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
AU5473400A (en)	1999-06-11	2001-01-02	Merck & Co., Inc.	Cyclopentyl modulators of chemokine receptor activity
JP2004506013A (ja)	2000-08-17	2004-02-26	メルク　エンド　カムパニー　インコーポレーテッド	シクロペンチル系ケモカイン受容体活性調節剤
UA74221C2 (uk) *	2000-11-28	2005-11-15	Пфайзер Продактс Інк.	Солі ізотіазол-4-карбоксаміду та їх використання як антигіперпроліферативних агентів
AU2002341327A1 (en) *	2001-11-29	2003-06-10	Pfizer Products Inc.	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
GEP20063872B (en) *	2001-12-12	2006-07-10	Pfizer Prod Inc	Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
MY129850A (en)	2002-04-29	2007-05-31	Merck Sharp & Dohme	Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2003093231A2 (en) *	2002-04-29	2003-11-13	Merck & Co., Inc.	Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
DE60321333D1 (de) *	2002-04-29	2008-07-10	Merck Sharp & Dohme	Tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridin-modulatoren der chemokin-rezeptor-aktivität
AR045875A1 (es) *	2003-10-27	2005-11-16	Merck & Co Inc	Procedimiento para la preparacion del antagonista ccr-2

2004
- 2004-10-25 NZ NZ546447A patent/NZ546447A/en unknown
- 2004-10-25 MX MXPA06004647A patent/MXPA06004647A/es active IP Right Grant
- 2004-10-25 UA UAA200605772A patent/UA81365C2/uk unknown
- 2004-10-25 CN CN2004800315947A patent/CN1870998B/zh not_active Expired - Fee Related
- 2004-10-25 BR BRPI0415836-9A patent/BRPI0415836A/pt not_active IP Right Cessation
- 2004-10-25 US US10/577,584 patent/US7473696B2/en not_active Expired - Fee Related
- 2004-10-25 CA CA2543201A patent/CA2543201C/en not_active Expired - Fee Related
- 2004-10-25 RU RU2006118352/04A patent/RU2317295C1/ru not_active IP Right Cessation
- 2004-10-25 AU AU2004287416A patent/AU2004287416C1/en not_active Ceased
- 2004-10-25 JP JP2006538125A patent/JP4542550B2/ja not_active Expired - Fee Related
- 2004-10-25 EP EP04796120A patent/EP1682135B1/de not_active Expired - Lifetime
- 2004-10-25 WO PCT/US2004/035069 patent/WO2005044264A1/en not_active Ceased
- 2004-10-25 AT AT04796120T patent/ATE517622T1/de not_active IP Right Cessation
- 2004-10-25 KR KR1020067008066A patent/KR20060101476A/ko not_active Ceased
2006
- 2006-04-04 ZA ZA200602752A patent/ZA200602752B/xx unknown
- 2006-04-06 IS IS8400A patent/IS8400A/is unknown
- 2006-04-20 IL IL175009A patent/IL175009A0/en unknown
- 2006-04-24 MA MA28957A patent/MA28104A1/fr unknown
- 2006-04-25 CO CO06039063A patent/CO5690606A2/es unknown
- 2006-04-26 EC EC2006006524A patent/ECSP066524A/es unknown
- 2006-05-24 NO NO20062377A patent/NO20062377L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2543201C (en)	2010-12-21
US7473696B2 (en)	2009-01-06
EP1682135A1 (de)	2006-07-26
MXPA06004647A (es)	2006-06-27
ZA200602752B (en)	2007-08-29
JP2007509940A (ja)	2007-04-19
EP1682135B1 (de)	2011-07-27
IS8400A (is)	2006-04-06
WO2005044264A1 (en)	2005-05-19
NZ546447A (en)	2009-02-28
ATE517622T1 (de)	2011-08-15
NO20062377L (no)	2006-05-24
AU2004287416C1 (en)	2010-09-09
ECSP066524A (es)	2006-10-10
CA2543201A1 (en)	2005-05-19
CN1870998B (zh)	2010-10-20
RU2317295C1 (ru)	2008-02-20
CN1870998A (zh)	2006-11-29
IL175009A0 (en)	2006-08-20
AU2004287416B2 (en)	2009-11-19
KR20060101476A (ko)	2006-09-25
MA28104A1 (fr)	2006-08-01
AU2004287416A1 (en)	2005-05-19
US20070135474A1 (en)	2007-06-14
BRPI0415836A (pt)	2007-01-02
EP1682135A4 (de)	2009-11-25
JP4542550B2 (ja)	2010-09-15
CO5690606A2 (es)	2006-10-31

Publication	Publication Date	Title
UA81365C2 (en)	2007-12-25	Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition
ES2550485T3 (es)	2015-11-10	Intermedios de inhibidores de la endopeptidasa neutra y método de preparación de los mismos
ES2266671T3 (es)	2007-03-01	Proceso para la produccion de estatinas semisinteticas a traves de nuevos intermediarios.
Breuning et al.	2003	An improved synthesis of aziridine-2, 3-dicarboxylates via azido alcohols—epimerization studies
KR20200008578A (ko)	2020-01-28	(3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법
RU2126379C1 (ru)	1999-02-20	ПРОИЗВОДНЫЕ ЦИКЛОПЕНТАН- ИЛИ ЦИКЛОПЕНТЕН -β- АМИНОКИСЛОТ И ИХ СОЛИ, КОМПОЗИЦИЯ, АКТИВНАЯ В ОТНОШЕНИИ ШТАММОВ S.AUREUS CANDIDA И TRICHOPHYTON
EP4695228A1 (de)	2026-02-18	Synthese von ras-inhibitoren
JP6596417B2 (ja)	2019-10-23	インドール化合物の製造方法
AU2004287810B2 (en)	2011-01-06	Process for the preparation of CCR-2 antagonist
CN107250100A (zh)	2017-10-13	制备nep抑制剂的工艺和中间体
ES2392207T3 (es)	2012-12-05	Proceso a partir de ácido shikímico para obtener oseltamivir fosfato
US7528264B2 (en)	2009-05-05	Hydride reduction process for preparing quinolone intermediates
AU2003299042A1 (en)	2004-04-08	Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
KR20110104933A (ko)	2011-09-23	피페리딘 유도체의 입체선택적 합성
RU2628081C2 (ru)	2017-08-14	Способы и промежуточные соединения для получения макроциклических ингибиторов протеазы hcv
JP2014240399A (ja)	2014-12-25	イソキノリン誘導体又はその塩の新規製造方法
EP1863761A1 (de)	2007-12-12	Verfahren zur herstellung von levetiracetam
KR20180115743A (ko)	2018-10-23	신규 독소, 및 이의 중간체를 제조하는 방법
BG63392B1 (bg)	2001-12-29	Производни на 5-нафтален-1-ил-1,3-диоксан, тяхното получаване и използването им като терапевтични средства
ES2383861B1 (es)	2013-05-08	Procedimiento de síntesis de intermedios de crambescidinas, de cimipronidina y de sus derivados.
JPWO2004058710A1 (ja)	2006-04-27	新規ベンズアミド誘導体及びその製造法
MXPA01002058A (en)	2002-03-05	Tan-1057 derivatives